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PURPOSE: Rheumatic heart disease (RHD) is an autoimmune disorder triggered by 
prolonged Streptococcus pyogenes infections.  MAb10F5 is an autoimmune antibody 
produced in response to S. pyogenes infections and contributes to progression of RHD.  
The complexity of molecular mimicry seen in S. pyogenes has made understanding 
mAb10F5 pathogenic mechanisms a great challenge, resulting in limited to no treatment 
options for RHD patients.  Recently, our lab found elevated levels of anti-phospholipid 
antibodies post administration of mAb10F5 epitope in Lewis rats, suggesting that 
mAb10F5 is an anti-phospholipid antibody.  Due to the significant function and 
abundance of the phospholipid cardiolipin in the mitochondrial membrane, we are 
interested in mitochondrial function in presence of mAb10F5 within human valvular 
interstitial cells. A second component of this study involves Mitsugumin-53 (MG53), a 
TRIM family protein.  MG53 has been investigated for its therapeutic potential in a 
variety of disease models, including cardiovascular disease. Very recently, MG53 was 
found to bind cardiolipin within mitochondria of cardiovascular cells under stressed 
conditions, leading to inhibition of cellular apoptosis and initiating membrane repair. 
Together, these two approaches shed light on mitochondrial function of HVIC cells after 
treatment with mAb10F5, MG53, and co-treatment including both.  Results from this 
study have the potential to impact the current understanding the role of mAb10F5 in 
RHD pathogenesis and potentially lead to new treatments that are less invasive than 
surgical procedures. METHODS: A novel approach to studying mAb10F5 and its effects 
on mitochondrial function in human valvular interstitial cardiac cells (HVIC) was carried 
out by (1) measuring reactive oxygen (ROS) production and (2) adenosine triphosphate 
(ATP) availability.  A mitoSOX assay assessed ROS production, while a luciferase ATP 
assay assessed ATP availability. RESULTS: The luciferase ATP assay showed that 
mAb10F5 treated HVIC resulted in significantly lower ATP concentrations than other 
groups. 3-Point mitoSOX Analysis showed marked increase in ROS production in 
mAb10F5 groups. CONCOLUSION: The results of this study suggest that mAb10F5 
may contribute to pathogenic mechanisms of diseases, such as Rheumatic Heart 
Disease, through disrupting mitochondrial function.  Our study also suggests that MG53 
may confer protective effects against mAb10F5 induced injury.   
 
